THZ2 is primarily used in cancer research as a potent and selective inhibitor of CDK7, a cyclin-dependent kinase involved in cell cycle regulation and transcription. It is particularly studied for its potential in targeting cancers driven by transcriptional dysregulation, such as triple-negative breast cancer and small cell lung cancer. By inhibiting CDK7, THZ2 disrupts the transcription of key oncogenes, leading to cancer cell death. Its application extends to preclinical studies where it helps in understanding the role of CDK7 in tumorigenesis and evaluating its efficacy as a therapeutic target. THZ2 is also utilized in combination therapies to enhance the effectiveness of other anticancer agents.